Literature DB >> 17457599

Relevance of the low-affinity type of the Fcgamma-receptor IIIa-polymorphism in bullous pemphigoid.

P Weisenseel1, S Martin, K Partscht, G Messer, J C Prinz.   

Abstract

Bullous pemphigoid (BP) is mediated by autoantibodies directed against molecules of the basement membrane zone. The biological function of antibodies involves binding to Fc-receptors expressed on human leucocytes. Recent studies suggested that a functional single-nucleotide-polymorphism of the Fcgamma-receptor IIIa (FcgammaRIIIa = CD16) at nucleotide 559 might predispose to the development of antibody-associated autoimmune disorders. This allelic difference affects the level of receptor affinity by predicting either a phenylalanine (F 158, low-affinity) or valine (V 158, high-affinity). We investigated if inherited frequencies of the high- and low-affinity FcgammaRIIIa polymorphism differed between patients with BP and healthy subjects. Genomic DNA from peripheral white blood cells was analyzed regarding FcgammaRIIIa polymorphism at nucleotide 559 by an established polymerase chain reaction. Sixty-seven Caucasian patients with BP and 88 healthy controls were included into the study. There was no significant difference in the distribution of the homozygous high-affinity FcgammaRIIIa-allotype (V/V) between BP-patients (14.9%) and healthy control subjects (20.5%). In contrast, 58.2% of the BP-patients were homozygous for the low-affinity FcgammaRIIIa-allotype (F/F), compared to 28.4% of the healthy controls (P = 0.001, OR 3.51). The frequencies of the polymorphism in the control group were in range of formerly published frequencies for healthy Caucasian subjects. Thus, the FcgammaRIIIa (158 F/V) polymorphism may modulate the susceptibility to acquire BP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457599     DOI: 10.1007/s00403-007-0755-8

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

Review 1.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Interaction of Psoriasis and Bullous Diseases.

Authors:  Teruki Dainichi; Kenji Kabashima
Journal:  Front Med (Lausanne)       Date:  2018-08-08

3.  Haplotypes of ABCB1 1236C >T (rs1128503), 2677G >T/A (rs2032582), and 3435C >T (rs1045642) in patients with bullous pemphigoid.

Authors:  Mariola Rychlik-Sych; Małgorzata Barańska; Michał Dudarewicz; Jadwiga Skrętkowicz; Agnieszka Żebrowska; Anna Woźniacka; Jacek Owczarek; Daria Orszulak-Michalak; Elżbieta Waszczykowska
Journal:  Arch Dermatol Res       Date:  2018-06-09       Impact factor: 3.017

Review 4.  Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.

Authors:  Angelo Ruggiero; Matteo Megna; Alessia Villani; Rosita Comune; Gabriella Fabbrocini; Francesca di Vico
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-14

5.  A Comparative Analysis of CD32A and CD16A Polymorphisms in Relation to Autoimmune Responses in Pemphigus Diseases and Subepithelial Autoimmune Blistering Disorders.

Authors:  Justyna Gornowicz-Porowska; Michał J Kowalczyk; Agnieszka Seraszek-Jaros; Monika Bowszyc-Dmochowska; Elżbieta Kaczmarek; Ryszard Żaba; Marian Dmochowski
Journal:  Genes (Basel)       Date:  2020-03-30       Impact factor: 4.096

6.  Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans.

Authors:  Juliane Russlies; Anke Fähnrich; Mareike Witte; Junping Yin; Sandrine Benoit; Regine Gläser; Claudia Günter; Rüdiger Eming; Jeanette Erdmann; Damian Gola; Yask Gupta; Maike Marleen Holtsche; Johannes S Kern; Inke R König; Dimitra Kiritsi; Wolfgang Lieb; Christian D Sadik; Miklós Sárdy; Franziska Schauer; Nina van Beek; Anke Weidinger; Margitta Worm; Detlef Zillikens; Enno Schmidt; Hauke Busch; Saleh M Ibrahim; Misa Hirose
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.